• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Conversion to proliferation signal inhibitors-based immunosuppressive regimen in kidney transplantation: to whom and when?

作者信息

Sahin S, Gürkan A, Uyar M, Dheir H, Turunç V, Varilsuha C, Kaçar S

机构信息

Department of Transplantation, Gaziosmanpasa Private Hospital, Istanbul, Turkey.

出版信息

Transplant Proc. 2011 Apr;43(3):837-40. doi: 10.1016/j.transproceed.2011.01.097.

DOI:10.1016/j.transproceed.2011.01.097
PMID:21486610
Abstract

BACKGROUND

Despite significant advances in kidney transplantation, long-term graft survival has not dramatically improved leading to strategies to change immunosuppression during the posttransplantation period. Proliferation signal inhibitors (PSI) sirolimus or everolimus possess immunosuppressive and antiproliferative properties.

METHODS

We evaluated 62 kidney transplant recipients who underwent conversion from a calcineurin inhibitors (CNI)- to a PSI-based regimen for various reasons. The statistical analysis used SPSS v.15.0 software. We compared calculated glomerular filtration rates (GFRs) before initiation of PSI (baseline) and at 6 months after conversion.

RESULTS

We converted to a PSI-based triple regimen at 172.0 ± 116.5 days after transplantation. The mean serum creatinine at the time of conversion was 2.0 ± 1.1 mg/dL, and it was 1.5 ± 0.7 mg/dL at 6 months after conversion. The rate of change in serum creatinine was -17.1 ± 23.5%. The mean calculated GFR at the time of conversion was 53.6 ± 25.5 mL/min and at 6 months after conversion was 65.8 ± 23.7 mL/min. The rate of change in calculated GFR was 37.9 ± 71.7% (16.4/59.4) at 6 months. Thus we observed significant improvements in creatinine and GFR (P values <.001) after conversion. The Improved GFR significantly correlated with prior dialysis duration and time to conversion (P = .025; P = .012). Patients who had a shorter duration on dialysis and shorter time to conversion experienced more benefit from conversion. Four of the 62 patients reported gastrointestinal toxicity, which resolved with dose reduction in 3 patients: 15 patients experienced acne; 16 reported oral ulcers. None of these toxicities resulted in discontinuation of PSI therapy. Serum cholesterol and tryglyceride levels tended to increase among the conversion group, but they did not show statistical significance.

CONCLUSION

We observed that minimization or withdrawal of CNI with addition of a PSI was a good treatment for deterioration of renal allograft function.

摘要

相似文献

1
Conversion to proliferation signal inhibitors-based immunosuppressive regimen in kidney transplantation: to whom and when?
Transplant Proc. 2011 Apr;43(3):837-40. doi: 10.1016/j.transproceed.2011.01.097.
2
Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination.转换为基于依维莫司的免疫抑制方案并减少或停用钙调神经磷酸酶抑制剂后肾移植受者的肾功能结局
Transplant Proc. 2009 Dec;41(10):4138-46. doi: 10.1016/j.transproceed.2009.08.065.
3
Excellent long-term results in de novo renal transplant recipients treated with proliferation signal inhibitors and reduced calcineurin inhibitors exposure.
Transplant Proc. 2008 Jul-Aug;40(6):1858-61. doi: 10.1016/j.transproceed.2008.05.047.
4
Long-term results of kidney transplantation with cyclosporine- and everolimus-based immunosuppression.基于环孢素和依维莫司免疫抑制的肾移植长期结果。
Transplant Proc. 2006 May;38(4):1018-9. doi: 10.1016/j.transproceed.2006.04.001.
5
Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.在扩大标准供体肾移植中采用基于西罗莫司的三联免疫抑制联合抗胸腺细胞球蛋白诱导治疗。
Nephrology (Carlton). 2008 Feb;13(1):80-6. doi: 10.1111/j.1440-1797.2007.00866.x.
6
Proliferation signal inhibitors and cardiac allograft vasculopathy.增殖信号抑制剂与心脏移植血管病变
Curr Opin Organ Transplant. 2008 Oct;13(5):543-50. doi: 10.1097/MOT.0b013e32830fdf70.
7
Tubular toxicity in sirolimus- and cyclosporine-based transplant immunosuppression strategies: an ancillary study from a randomized controlled trial.基于西罗莫司和环孢素的移植免疫抑制策略中的肾小管毒性：一项随机对照试验的辅助研究。
Am J Kidney Dis. 2010 Feb;55(2):335-43. doi: 10.1053/j.ajkd.2009.09.004. Epub 2009 Nov 17.
8
Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.肾移植术后早期维持性免疫抑制的最小化：一项中期分析。
Transplantation. 2009 Aug 15;88(3):421-8. doi: 10.1097/TP.0b013e3181af1df6.
9
Sirolimus conversion after liver transplantation: improvement in measured glomerular filtration rate after 2 years.
Transplant Proc. 2005 Dec;37(10):4416-23. doi: 10.1016/j.transproceed.2005.10.019.
10
[Benefits of proliferation signal inhibitors beyond immunosuppression. Vascular protection and experience in heart transplantation].[增殖信号抑制剂在免疫抑制之外的益处。血管保护及心脏移植经验]
Nephrol Ther. 2009 Dec;5 Suppl 6:S379-84. doi: 10.1016/S1769-7255(09)73429-7.

引用本文的文献

1
Sirolimus potentiated angioedema: A case report and review of the literature.西罗莫司加重血管性水肿：一例病例报告及文献综述。
Open Med (Wars). 2024 Jan 9;19(1):20230884. doi: 10.1515/med-2023-0884. eCollection 2024.
2
Everolimus-associated stomatitis in a patient who had renal transplant.一名肾移植患者出现的依维莫司相关性口腔炎。
BMJ Case Rep. 2016 Oct 19;2016:bcr2016217513. doi: 10.1136/bcr-2016-217513.
3
Open-Label, Randomized Study of Transition From Tacrolimus to Sirolimus Immunosuppression in Renal Allograft Recipients.
肾移植受者从他克莫司转换为西罗莫司免疫抑制的开放标签随机研究。
Transplant Direct. 2016 Mar 3;2(4):e69. doi: 10.1097/TXD.0000000000000579. eCollection 2016 Apr.
4
Oscillatory mTOR inhibition and Treg increase in kidney transplantation.肾移植中振荡性mTOR抑制与调节性T细胞增加
Clin Exp Immunol. 2015 Nov;182(2):230-40. doi: 10.1111/cei.12669. Epub 2015 Aug 28.